COMP <GO>
EXEL vs BIIB // EV/EBITDA & P/E VALUATION
Exelixis Inc. (NASDAQ) VS. Biogen Inc. (NASDAQ) • 15-METRIC TALLY: EXEL 10
— BIIB 3
▲ EV/EBITDA & P/E VALUATION LEADER: EXEL
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
valuation
18.4x
LAST: $253.62 (+1.59%) • MKT CAP: $36.90B
valuation
22.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. BIIB)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | BIIB | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 75.70% | +20.30 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 6.40% | +28.70 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 18.4x | 22.3x | -3.90 | EXEL | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 5.56% | -0.22 | BIIB | /fcf-yield <GO> |
| Operating Margin | 37.60% | 15.90% | +21.70 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 13.10% | +20.60 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 2.20% | +4.80 | EXEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 3.70 | +12.94 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 61.8 | +1.50 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 1.10 | -0.14 | BIIB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 26.5x | -7.00 | EXEL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $36.90B | -$20.50B | BIIB | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | BIIB REV | EXEL GROSS % | BIIB GROSS % | EXEL FCF | BIIB FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $9.89B | 96.4% | 75.7% | $875.8M | $2.05B |
| FY 2024 | $2.17B | $9.68B | 96.5% | 76.1% | $671.5M | $2.72B |
| FY 2023 | $1.83B | $9.84B | — | — | $251.0M | $1.10B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
BIIB // BETA 1.10